| Name | Title | Contact Details |
|---|
WellCentive is a pioneer in business and clinical intelligence registry EHR healthcare information technology.
MedRisk is the leading provider of managed physical medicine for the workers` compensation industry and related market sectors. Unified through a uniquely integrated, US-based support model, we pride ourselves in combining clinical expertise with highly personal service and responsiveness. This focus allows us to offer distinct value to each stakeholder in the workers` comp process – carriers and TPAs, employers, adjusters and case managers, physicians, network providers and the patients themselves. In short, we`re here for you; at MedRisk, you`re never just a number – you`re an individual who deserves a solution tailored to your exact needs. We`re here to help you reach your goals and improve your outcomes – whatever they may be.
Ovid Therapeutics is a biopharmaceutical company focused exclusively on developing impactful medicines for patients and families living with rare neurological disorders. Ovid`s drug candidate, OV101, is currently in development for the treatment of symptoms of Angelman syndrome and Fragile X syndrome. Ovid is also developing OV935 in collaboration with Takeda Pharmaceutical Company Limited for the treatment of rare epileptic encephalopathies. Ovid has initiated the Phase 2 STARS trial of OV101 in adults with Angelman syndrome and a Phase 1 trial in adolescents with Angelman and Fragile X syndrome to identify doses suitable for younger patients.
Kite Pharma, founded in 2009, is dedicated to the development and commercialization of novel cancer immunotherapy products designed to harness the power of a patient’s own immune system to fight tumor cells. Kite’s lead programs are in collaboration with the National Cancer Institute (NCI) and are being studied through the NCI’s Surgery Branch led by Steven A. Rosenberg, MD, PhD, who has pioneered immunotherapy approaches for cancer for more than two decades. This research has resulted in breakthrough clinical findings, including results from an NCI Phase 1/2a trial being presented at this year’s American Society of Hematology (ASH) Annual Meeting. Based on this progress and momentum, Kite plans to initiate a company-sponsored multicenter clinical program in aggressive non-Hodgkin’s lymphoma, with additional filings expected for other eACT™ products in diverse oncology indications.
Rose Medical Group is a not-for-profit, membership-based, multi-specialty Physician Hospital Organization and IPA affiliated with the HealthONE Rose Medical Center in Denver, Colorado.